PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma.

ABSTRACT: Emerging immunotherapies quest for better patient stratification in cancer treatment decisions. Moderate response rates of PD-1 inhibition in gastric and esophagogastric junction cancers urge for meaningful human model systems that allow for investigating immune responses ex vivo. Here, the standardized patient-derived tissue culture (PDTC) model was applied to investigate tumor response to the PD-1 inhibitor Nivolumab and the CD3/CD28 t-lymphocyte activator ImmunoCult^TM. Resident t-lymphocytes, tumor proliferation and apoptosis, as well as bulk gene expression data were analyzed after 72 h of PD-1 inhibition either as monotherapy or combined with Oxaliplatin or ImmunoCult^TM. Individual responses to PD-1 inhibition were found ex vivo and combination with

SUBMITTER: Hußtegge M 

PROVIDER: S-EPMC8381835 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature